A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
University of Nebraska
Tango Therapeutics, Inc.
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
Azienda Ospedaliera di Padova
PharmaMar
Instituto do Cancer do Estado de São Paulo
NGM Biopharmaceuticals, Inc
Shenzhen BinDeBio Ltd.
Stanford University